Physician profile
Mark H Salley
NPI 1053381012
$4,011.66
in general payments reported to CMS, 2019-2025
36 companies · $417 in 2025
The $417 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $50.56 · 2021: $306 · 2022: $975 · 2023: $978 · 2024: $414 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.19 |
| Education | $165.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $880.45 | 2019-2025 | Vraylar, Botox, Lo Loestrin Fe |
| Allergan, INC. | $569.16 | 2019-2022 | |
| Astellas Pharma US INC | $347.95 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $265.17 | 2019-2024 | |
| Exeltis, USA INC. | $222.66 | 2022-2025 | Slynd |
| Sumitomo Pharma America, INC. | $189.75 | 2023-2025 | Myfembree, Gemtesa |
| Duchesnay USA Incorporated | $186.72 | 2019 | |
| Aspira Women'S Health INC | $163.02 | 2022 | |
| Daiichi Sankyo INC. | $132.45 | 2019-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $103.76 | 2019-2025 | |
| Novo Nordisk INC | $100.78 | 2019-2024 | Wegovy |
| Galderma Laboratories, L.P. | $89.76 | 2023-2024 | Dysport |
| Sage Therapeutics, LLC | $70.17 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $55.72 | 2022 | |
| Mayne Pharma Commercial LLC | $47.36 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $47.36 | 2022-2024 | |
| Coopersurgical, INC. | $47.29 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Amgen INC. | $42.35 | 2019-2023 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $40.94 | 2022 | |
| Therapeuticsmd, INC. | $36.54 | 2019 | |
| Vertical Pharmaceuticals, LLC | $36.16 | 2019 | |
| Si-Bone, INC. | $36.12 | 2019 | |
| Rochester Medical Corporation | $31.35 | 2021-2022 | |
| Medtronic, INC. | $30.61 | 2021-2023 | Interstim |
| Boston Scientific Corporation | $29.27 | 2025 | Solyx Sis System |
| Dexcom, INC. | $27.83 | 2023 | Dexcom G6 Transmitter |
| Amag Pharmaceuticals, INC. | $25.05 | 2019-2020 | |
| Lupin INC. | $23.91 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $21.39 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $21.23 | 2022 | |
| Meditrina | $20.67 | 2023 | |
| Scynexis, INC. | $16.32 | 2022 | |
| Exact Sciences Corporation | $14.57 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $14.12 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.88 | 2019 | |
| Coloplast Corp | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Salley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.